Literature DB >> 12455080

Percutaneous cardiopulmonary support in critical patients needing coronary interventions with stents.

José Suárez de Lezo1, Manuel Pan, Alfonso Medina, Djordje Pavlovic, Miguel Romero, José Segura, Martin Ruiz, Soledad Ojeda, Juan Muñoz, Marcos Rodriguez.   

Abstract

Percutaneous cardiopulmonary support (CPS) has proven to be a technique of value in high-risk coronary patients undergoing percutaneous balloon angioplasty. Since May 1994, we have combined the use of CPS and coronary stent revascularization in 92 patients. In 68 of them, the CPS was used as a prophylactic procedure (group 1); in the remaining 24, the CPS was used as an emergency procedure to stabilize and even resuscitate patients with acute myocardial infarction and circulatory collapse, in order to attempt urgent percutaneous coronary stent treatment (group 2). Primary success was achieved in 66 patients from group 1 (97%). One patient died and another had a myocardial infarction. After 28 +/- 19 months of follow-up, 20 patients (30%) from group 1 had a major adverse cardiac event. The remaining 46 patients (68%) are alive, with persistent clinical benefit. In group 2, reperfusion and stent treatment was always achieved. However, 14 patients had an in-hospital death. Five patients from group 2 had a major adverse event at follow-up (47 +/- 20 months). Nine patients (38%) remain at present in functional class I-II. Percutaneous CPS provides safe conditions to accomplish stent coronary revascularization in high-risk patients and those with acute myocardial infarction and failing heart. Long-term follow-up of survivors shows persistent benefit in most patients. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12455080     DOI: 10.1002/ccd.10340

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  7 in total

1.  Short-term Mechanical Circulatory Support with a Centrifugal Pump - Results of Peripheral Extracorporeal Membrane Oxygenator According to Clinical Situation.

Authors:  Woo Surng Lee; Hyun Keun Chee; Meong Gun Song; Yo Han Kim; Je Kyoun Shin; Jun Seok Kim; Song Am Lee; Jae Joon Hwang
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2011-02-12

2.  Myocardial protection of early extracorporeal membrane oxygenation (ECMO) support for acute myocardial infarction with cardiogenic shock in pigs.

Authors:  Gang-jie Zhu; Li-na Sun; Xing-hai Li; Ning-fu Wang; Hong-hai Wu; Chen-xing Yuan; Qiao-qiao Li; Peng Xu; Ya-qi Ren; Bao-gen Mao
Journal:  Heart Vessels       Date:  2014-09-27       Impact factor: 2.037

3.  Preoperative Extracorporeal Membrane Oxygenation for Severe Ischemic Mitral Regurgitation - 2 case reports -.

Authors:  Tae Sik Kim; Chan-Young Na; Jong Hyun Baek; Jae-Hyun Kim; Sam-Sae Oh
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2011-06-11

4.  Cardiopulmonary resuscitation with assisted extracorporeal life support during cardiac arrest caused by drug-eluting stent thrombosis: a case report.

Authors:  Ju-Hyun Lee; Sang-Heon Park; In Ae Song
Journal:  Korean J Anesthesiol       Date:  2014-05-26

5.  Percutaneous cardiopulmonary support-supported percutaneous coronary intervention: a single center experience.

Authors:  Sung Soo Cho; Chang-Myung Oh; Ji-Yong Jang; Hee Tae Yu; Woo-Dae Bang; Jung-Sun Kim; Young-Guk Ko; Donghoon Choi; Myeong-Ki Hong; Won-Heum Shim; Seung-Yun Cho; Yangsoo Jang
Journal:  Korean Circ J       Date:  2011-06-30       Impact factor: 3.243

6.  Results of Extracorporeal Membrane Oxygenation (ECMO) Support before Coronary Reperfusion in Cardiogenic Shock with Acute Myocardial Infarction.

Authors:  Eui Suk Chung; Cheong Lim; Hae-Young Lee; Jin-Ho Choi; Jeong-Sang Lee; Kay-Hyun Park
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2011-08-18

7.  Earlier application of percutaneous cardiopulmonary support rescues patients from severe cardiopulmonary failure using the APACHE III scoring system.

Authors:  Suk-Won Song; Hong-Suk Yang; Sak Lee; Young-Nam Youn; Kyung-Jong Yoo
Journal:  J Korean Med Sci       Date:  2009-11-09       Impact factor: 2.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.